Equities Analysts Offer Predictions for UTHR FY2026 Earnings

United Therapeutics Corporation (NASDAQ:UTHR) – Equities researchers at Cantor Fitzgerald increased their FY2026 earnings per share estimates for shares of United Therapeutics in a report released on Wednesday, September 10th. Cantor Fitzgerald analyst O. Brayer now forecasts that the biotechnology company will earn $31.56 per share for the year, up from their prior estimate of $31.44. Cantor Fitzgerald has a “Overweight” rating and a $525.00 price objective on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

A number of other analysts also recently issued reports on UTHR. Morgan Stanley reduced their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Oppenheimer lifted their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. HC Wainwright lifted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, September 4th. Finally, Bank of America lifted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $438.85.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $405.02 on Thursday. The company has a market cap of $18.27 billion, a P/E ratio of 15.81, a P/E/G ratio of 6.17 and a beta of 0.62. The firm’s fifty day moving average is $318.53 and its two-hundred day moving average is $307.56. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $436.95.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business’s revenue was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.85 earnings per share.

Insider Activity at United Therapeutics

In other news, Director Tommy G. Thompson sold 4,560 shares of United Therapeutics stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $403.36, for a total value of $1,839,321.60. Following the sale, the director owned 8,480 shares in the company, valued at $3,420,492.80. This trade represents a 34.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $385.21, for a total transaction of $4,237,310.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $14,168,409.01. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 128,816 shares of company stock valued at $45,836,113 in the last quarter. 10.30% of the stock is currently owned by insiders.

Institutional Trading of United Therapeutics

Several institutional investors have recently modified their holdings of UTHR. Osaic Holdings Inc. lifted its stake in shares of United Therapeutics by 271.0% in the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after buying an additional 33,662 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of United Therapeutics by 0.6% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,059 shares of the biotechnology company’s stock worth $2,603,000 after buying an additional 50 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in shares of United Therapeutics in the second quarter worth about $214,000. Marex Group plc purchased a new position in shares of United Therapeutics in the second quarter worth about $316,000. Finally, State of Wyoming purchased a new position in shares of United Therapeutics in the second quarter worth about $55,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.